144 ·Filed Sep 15, 2026

DNA

Ginkgo Bioworks Holdings, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed17d ago SEC0001959173-26-006973
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

No actionable signal. This is a routine, small-dollar director sale of vested RSUs. Monitor for any larger insider sales or changes in insider filing patterns ahead of next earnings.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+5d
DNA ▲ +12.73% at T+5d
NEUTRAL call ✓ call won +12.73% · α vs SPY +11.91% · entry $6.99 → $7.88
Next anchor: T+20d in 11d
Latest observation: T+8 +48.55% FF3 residual α
Entry anchored
Sep 15, 11:47 AM ET
via 1-min bar
T+1d
+4.01%
call +4.01% · α +3.68%
$7.27
settled 16d ago
T+5d
+12.73%
call +12.73% · α +11.91%
$7.88
settled 10d ago
T+20d
—
call — · α —
—
in 11d
T+60d
—
call — · α —
—
in 2mo

Price Chart

Loading chart...

Executive Summary

Director Christian O. Henry filed a Form 144 notice to sell 5,000 Class A shares (~$35,406 at ~$7.08/sh), representing a routine, small-dollar sale by a director. The shares were acquired via restricted stock vesting from 2022-2023. Given the minimal size relative to market cap ($451M) and the director's role (not CEO/CFO), this filing is routine and carries no material signal.

Key Facts

  • Director Christian O. Henry filed Form 144 to sell 5,000 Class A shares.
  • Estimated proceeds: ~$35,406 based on filing date price.
  • Shares were acquired through restricted stock vesting from March 2022 to April 2023.
  • Sale represents a small fraction of director's holdings and company market cap ($451M).

Financial Impact

~$35,406 sale by a director — immaterial relative to $451M market cap.

Risk Factors

  • Form 144 is an intent to sell — the sale may not be executed.
  • No material risk to equity value from this filing.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
0% bullish (10 analysts)

Investment Themes

Genomics & Gene Editing

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-006973
Document: 0001959173-26-006973-index.html0001959173-26-006973
Document: 0001959173-26-006973.txt0001959173-26-006973
3 reports for DNA
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for DNA — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
144
NEUTRAL ★ 2/10
$6.99 $7.88▲ +12.73%▲ +11.91%$12.26 (+75.32%)
Apr 9, 2026
25w ago
Insider Cluster
BEARISH ★ 6/10
$6.43 $7.95▼ −23.64%▼ −20.45%$12.26 (−90.59%)
Apr 9, 2026
25w ago
Insider Cluster
BEARISH ★ 6/10
$6.43 $7.95▼ −23.64%▼ −20.45%$12.26 (−90.59%)
Showing 3 of 3

US Market Status

Market Open — Closes in 3h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access